<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2023-5358</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-5358</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭПИДЕМИОЛОГИЯ И ФАКТОРЫ РИСКА</subject></subj-group></article-categories><title-group><article-title>Интегрированное решение для пациентов очень высокого сердечно-сосудистого риска. Окончательные результаты</article-title><trans-title-group xml:lang="en"><trans-title>Integrated solution for patients of a very high cardiovascular risk. Final results</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0108-5996</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Усова</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Usova</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Врач-кардиолог, младший научный сотрудник НИЛ нарушений липидного обмена и атеросклероза.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><email xlink:type="simple">zvartau_ne@almazovcentre.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3664-5383</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ионов</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ionov</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Врач-кардиолог, кандидат медицинских наук, научный сотрудник НИЛ патогенеза и терапии артериальной гипертензии Института сердца и сосудов.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><email xlink:type="simple">zvartau_ne@almazovcentre.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9845-331X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алиева</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Alieva</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Врач-кардиолог, кандидат медицинских наук, зав. НИЛ нарушений липидного обмена и атеросклероза НЦМУ "Центр персонализированной медицины", руководитель Центра Атеросклероза и нарушений липидного обмена.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><email xlink:type="simple">zvartau_ne@almazovcentre.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9871-3452</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Авдонина</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Avdonina</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Врач-кардиолог, заведующий отделом информационного обеспечения и телемедицины.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><email xlink:type="simple">zvartau_ne@almazovcentre.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5656-3978</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яковлев</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Yakovlev</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат медицинских наук, начальник службы по развитию регионального здравоохранения Управления по реализации федеральных проектов, зав. НИЛ технологий прогнозирования риска развития сердечно-сосудистых осложнений НЦМУ "Центр персонализированной медицины", доцент кафедры факультетской терапии Лечебного факультета Института медицинского образования.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><email xlink:type="simple">zvartau_ne@almazovcentre.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6533-5950</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Звартау</surname><given-names>Н. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Zvartau</surname><given-names>N. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат медицинских наук, доцент, заместитель генерального директора по работе с регионами, доцент кафедры факультетской терапии Лечебного факультета Института медицинского образования.</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>St. Petersburg</p></bio><email xlink:type="simple">zvartau_ne@almazovcentre.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ Национальный медицинский исследовательский центр им. В. А. Алмазова, Минздрав России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Center</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>20</day><month>03</month><year>2023</year></pub-date><volume>28</volume><issue>2</issue><fpage>5358</fpage><lpage>5358</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Усова Е.И., Ионов М.В., Алиева А.С., Авдонина Н.Г., Яковлев А.Н., Звартау Н.Э., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Усова Е.И., Ионов М.В., Алиева А.С., Авдонина Н.Г., Яковлев А.Н., Звартау Н.Э.</copyright-holder><copyright-holder xml:lang="en">Usova E.I., Ionov M.V., Alieva A.S., Avdonina N.G., Yakovlev A.N., Zvartau N.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/5358">https://russjcardiol.elpub.ru/jour/article/view/5358</self-uri><abstract><p>Меры вторичной профилактики следует активно внедрять на всех этапах лечения и реабилитации пациентов после перенесенного острого коронарного синдрома (ОКС). Перспективна интеграция в клиническую практику удаленного наблюдения пациентов с телеметрической передачей витальных и лабораторных данных.</p><sec><title>Цель</title><p>Цель. Оценка клинической и пациент-ориентированной эффективности разработанной и внедренной схемы комбинированного очного и телемедицинского наблюдения пациентов, недавно перенесших ОКС, на протяжении 12 мес.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Для заключительного анализа использованы данные 84 (из 100 включенных) пациентов (медиана возраста 56 (50;61) лет, 70 мужчин) с артериальной гипертензией и/или сахарным диабетом тип 2, которые в течение 12 предшествующих месяцев перенесли ОКС и эндоваскулярную реваскуляризацию, при этом их уровень холестерина липопротеидов низкой плотности (ХС-ЛНП) находился выше отметки в 2,4 ммоль/л. Стандартная практика ведения пациентов была дополнена телемедицинской программой, функционал которой включал электронные дневники самоконтроля артериального давления (АД) и липидограммы, а также сервис текстовых телеконсультаций с врачом. Обязательные очные визиты проводились через 3 и 12 мес. от даты включения. Основная конечная точка — ∆ХС-ЛНП. Оценены дополнительные клинические и пациент-ориентированные конечные точки.</p></sec><sec><title>Результаты</title><p>Результаты. Выявлено значимое снижение ХС-ЛНП на 1,6 (-2,3;-0,9) ммоль/л к концу наблюдения. Кроме изначального уровня ХС-ЛНП, с его снижением были связаны: а) высокая приверженность пациентов к ведению дневников самоконтроля АД и липидограммы (β=0,7), б) количество отправленных врачом текстовых сообщений в 1-й мес. наблюдения (β=0,04). У более приверженных пациентов ∆ХС-ЛНП была выше на 0,49 ммоль/л (95% доверительный интервал (ДИ) -1,2; -0,1), после поправки на основные количественные ковариаты. У 35 пациентов (42%) удалось добиться целевого ХС-ЛНП, у 60 пациентов (71%) — снижения на ≥1 ммоль/л. При этом приверженные пациенты вдвое чаще достигали целевого ХС-ЛНП (отношение шансов 2,2; 95% ДИ (0,6; 3,8)), нежели неприверженные. В положительную сторону изменились и другие индикаторы липидограммы. Показано снижение офисного систолического АД на 5,8 мм рт.ст. (р=0,03). Количество сообщений врача пациенту превышало таковое от пациентов к врачу (медианы 143 и 111 консультаций на пациента в год, соответственно). Качество жизни улучшилось, но только в части эмоционального компонента. Оценка удовлетворенности программой оставалась высокой на всех этапах исследования.</p></sec><sec><title>Заключение</title><p>Заключение. Показана эффективность комбинированного типа оказания медицинской помощи (с интеграцией телемониторинга) у пациентов после перенесенного ОКС. Приверженность к самоконтролю АД, а также активная консультативная поддержка на первых этапах реабилитации, способствует дополнительному динамическому контролю показателей липидного спектра, своевременной коррекции гиполипидемической терапии с достижением целевого уровня ХС-ЛНП. Большинство пациентов не испытывало трудностей при использовании программы, и готовы рекомендовать такой путь наблюдения другим пациентам.</p></sec></abstract><trans-abstract xml:lang="en"><p>Secondary prevention should be actively implemented at all stages of treatment and rehabilitation of patients after acute coronary syndrome (ACS). The integration of remote monitoring of patients with the transfer of vital and laboratory data into clinical practice seems promising.</p><sec><title>Aim</title><p>Aim. To evaluate the clinical and patient-centered effectiveness of the original 12-month combined face-to-face and telecare program in patients with recent ACS.</p></sec><sec><title>Material and methods</title><p>Material and methods. For the present analysis the data from 84 (out of 100) patients (median age, 56 (50;61) years, 70 males) was used. These patients had to have hypertension and/or type 2 diabetes and an ACS with percutaneous revascularization within 12 months. Their low-density lipoprotein cholesterol (LDL-C) had to be above 2,4 mmol/L. Telehealth program supplemented routine care. A program contained electronic self-control diaries for blood pressure (BP) and lipid profile, and teleconsulting service (text chat). Mandatory face-to-face visits were carried out at 3 and 12 months after the enrollment. The primary end point was ∆LDL-C. Additional clinical and patient-specific endpoints were evaluated.</p></sec><sec><title>Results</title><p>Results. At the 12-month visit, there was a significant decrease in LDL-C by 1,6 (-2,3;-0,9) mmol/L. Besides the initial LDL-C value, the decrease in LDL-C was associated with the proper adherence to keeping diaries of BP and lipid profile (β=0,7), and the number of text messages sent by the doctor in the 1st month after the enrollment (β=0,04). In more adherent patients, the ∆LDL-C was greater by 0,49 mmol/L (95% CI (-1,2; -0,1)) after adjustment for abovementioned covariates. In 35 patients (42%), target LDL-C was achieved, in 60 patients (71%) — a decrease ≥1 mmol/l. Other lipids also have changed for the better. Moreover, adherent patients were twice as likely to achieve the target LDL-C (OR 2,2; 95% CI (0,6; 3,8)) than non-adherent ones. A decrease in office systolic BP by 5,8 mm Hg was shown (p=0,03). The number of physician-to-patient messages exceeded those from patients to physician (median 143 and 111 per patient for 12 months, respectively). The quality of life has improved, but only in terms of emotions. Satisfaction with the program remained high at all timepoints of the study.</p></sec><sec><title>Conclusion</title><p>Conclusion. Our study showed the effectiveness of the integrated care in ACS patients with the telehealth tool included. Commitment to BP self-monitoring, as well as active consultative support at the first stages of rehabilitation, contributes to additional dynamic control of lipid profile, timely correction of lipid-lowering therapy with the achievement of the target LDL-C level. Most of the patients did not experience any difficulties in using the program and are ready to recommend integrated approach to other peers.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>дислипидемия</kwd><kwd>острый коронарный синдром</kwd><kwd>телемедицина</kwd><kwd>ингибиторы ГМГ-КоА-редуктазы (статины)</kwd><kwd>самостоятельный контроль</kwd><kwd>обучение пациентов</kwd><kwd>качество жизни</kwd><kwd>удобство использования</kwd></kwd-group><kwd-group xml:lang="en"><kwd>hypertension</kwd><kwd>dyslipidemia</kwd><kwd>acute coronary syndrome</kwd><kwd>telehealth</kwd><kwd>HMG-CoA reductase inhibitors (statins)</kwd><kwd>self-management</kwd><kwd>patient education</kwd><kwd>quality of life</kwd><kwd>usability</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Материал подготовлен в рамках Договора о сотрудничестве между ФГБУ "НМИЦ им. В. А. Алмазова" Минздрава России и АО "Санофи Россия" от 18.04.2019г. Сбор и анализ данных в проекте с последующей их публикацией осуществляется ФГБУ "НМИЦ им. В. А. Алмазова" Минздрава России независимо и без участия компании Санофи. Авторский коллектив выражает благодарность Орбеладзе Н. В., клиническому ординатору очной формы обучения по специальности "кардиология" ФГБУ "НМИЦ им. В. А. Алмазова" Минздрава России, за помощь в отборе пациентов, а также Ходыревой А. А., врачу-методисту ФГБУ "НМИЦ им. В. А. Алмазова" Минздрава России, за помощь в подготовке базы данных для проведения анализа пациент-ориентированных конечных точек</funding-statement><funding-statement xml:lang="en">The material was prepared within the Cooperation Agreement between the Almazov National Medical Research Center and AO Sanofi Russia dated April 18, 2019. The collection and analysis of data in the project with their subsequent publication is carried out by the Almazov National Medical Research Center independently and without the participation of Sanofi. Authoring team is grateful to Orbeladze N. V., full-time cardio­logy resident of the Almazov National Medical Research Center, for assistance in the selection of patients, as well as Khodyreva A. A., methodologist of the Almazov National Medical Research Center, for assistance in preparing a database for analyzing patient-centered endpoints.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Zafeiropoulos S, Farmakis I, Kartas A, et al. Risk for Recurrent Cardiovascular Events and Expected Risk Reduction With Optimal Treatment 1 Year After an Acute Coronary Syndrome. Am J Cardiol. 2020;133:7-14. doi:10.1016/j.amjcard.2020.07.046.</mixed-citation><mixed-citation xml:lang="en">Zafeiropoulos S, Farmakis I, Kartas A, et al. Risk for Recurrent Cardiovascular Events and Expected Risk Reduction With Optimal Treatment 1 Year After an Acute Coronary Syndrome. Am J Cardiol. 2020;133:7-14. doi:10.1016/j.amjcard.2020.07.046.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23:636-48. doi:10.1177/2047487315569401.</mixed-citation><mixed-citation xml:lang="en">Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23:636-48. doi:10.1177/2047487315569401.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hoedemaker NPG, Damman P, Ottervanger JP, et al. Trends in optimal medical therapy prescription and mortality after admission for acute coronary syndrome: a 9-year experience in a real-world setting. Eur Heart J Cardiovasc Pharmacother. 2018;4:102-10. doi:10.1093/ehjcvp/pvy005.</mixed-citation><mixed-citation xml:lang="en">Hoedemaker NPG, Damman P, Ottervanger JP, et al. Trends in optimal medical therapy prescription and mortality after admission for acute coronary syndrome: a 9-year experience in a real-world setting. Eur Heart J Cardiovasc Pharmacother. 2018;4:102-10. doi:10.1093/ehjcvp/pvy005.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Butalia S, Lee-Krueger RCW, McBrien KA, et al. Barriers and Facilitators to Using Statins: A Qualitative Study With Patients and Family Physicians. CJC Open. 2020;2:530-8. doi:10.1016/j.cjco.2020.07.002.</mixed-citation><mixed-citation xml:lang="en">Butalia S, Lee-Krueger RCW, McBrien KA, et al. Barriers and Facilitators to Using Statins: A Qualitative Study With Patients and Family Physicians. CJC Open. 2020;2:530-8. doi:10.1016/j.cjco.2020.07.002.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163-70. doi:10.1093/eurheartj/ehu505.</mixed-citation><mixed-citation xml:lang="en">Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163-70. doi:10.1093/eurheartj/ehu505.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Eijsvogels TMH, Maessen MFH, Bakker EA, et al. Association of Cardiac Rehabili­tation With All-Cause Mortality Among Patients With Cardiovascular Disease in the Netherlands. JAMA Netw Open. 2020;3:e2011686. doi:10.1001/jamanetworkopen.2020.11686.</mixed-citation><mixed-citation xml:lang="en">Eijsvogels TMH, Maessen MFH, Bakker EA, et al. Association of Cardiac Rehabili­tation With All-Cause Mortality Among Patients With Cardiovascular Disease in the Netherlands. JAMA Netw Open. 2020;3:e2011686. doi:10.1001/jamanetworkopen.2020.11686.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Rauch B, Davos CH, Doherty P, et al. The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: A systematic review and meta-analysis of randomized and non-randomized studies — The Cardiac Rehabilitation Outcome Study (CROS). Eur J Prev Cardiol. 2016;23:1914-39. doi:10.1177/2047487316671181.</mixed-citation><mixed-citation xml:lang="en">Rauch B, Davos CH, Doherty P, et al. The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: A systematic review and meta-analysis of randomized and non-randomized studies — The Cardiac Rehabilitation Outcome Study (CROS). Eur J Prev Cardiol. 2016;23:1914-39. doi:10.1177/2047487316671181.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">West RR, Jones DA, Henderson AH. Rehabilitation after myocardial infarction trial (RAMIT): multi-centre randomised controlled trial of comprehensive cardiac rehabilitation in patients following acute myocardial infarction. Heart Br Card Soc. 2012;98:637-44. doi:10.1136/heartjnl-2011-300302.</mixed-citation><mixed-citation xml:lang="en">West RR, Jones DA, Henderson AH. Rehabilitation after myocardial infarction trial (RAMIT): multi-centre randomised controlled trial of comprehensive cardiac rehabilitation in patients following acute myocardial infarction. Heart Br Card Soc. 2012;98:637-44. doi:10.1136/heartjnl-2011-300302.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ионов М. В., Конради А. О. Телемедицинское наблюдение пациентов с артериальной гипертензией: кому, как и как долго? Артериальная Гипертензия. 2022;28(2):108-25. doi:10.18705/1607-419X-2022-28-2-108-125.</mixed-citation><mixed-citation xml:lang="en">Ionov MV, Konradi AO. Telehealth in hypertensive patients: to whom, how and for how long? "Arterial’naya Gipertenziya". ("Arterial Hypertension"). 2022;28(2):108-25. (In Russ.) doi:10.18705/1607-419X-2022-28-2-108-125.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Мареев Ю. В., Зинченко А. О., Мясников Р. П. и др. Применение телеметрии у больных с хронической сердечной недостаточностью. Кардиология. 2019;59(9S):4-15. doi:10.18087/cardio.n530.</mixed-citation><mixed-citation xml:lang="en">Mareev YuV, Zinchenko AO, Myasnikov RP, et al. Telemonitoring in patients with chronic heart failure. Kardiologiia. 2019;59(9S):4-15. (In Russ.) doi:10.18087/cardio.n530.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Khan NA, Stergiou GS, Omboni S, et al. Virtual management of hypertension: lessons from the COVID-19 pandemic-International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. J Hypertens. 2022;40:1435-48. doi:10.1097/HJH.0000000000003205.</mixed-citation><mixed-citation xml:lang="en">Khan NA, Stergiou GS, Omboni S, et al. Virtual management of hypertension: lessons from the COVID-19 pandemic-International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. J Hypertens. 2022;40:1435-48. doi:10.1097/HJH.0000000000003205.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Павлюк Е. И., Ионов М. В., Алиева А. С. и др. Интегрированное решение для пациентов очень высокого сердечно-сосудистого риска. Обоснование и дизайн пилотного исследования. Российский кардиологический журнал. 2021;26(7):4608. doi:10.15829/1560-4071-2021-4608.</mixed-citation><mixed-citation xml:lang="en">Pavlyuk EI, Ionov MV, Alieva AS, et al. Integrated solution for very high cardiovascular risk patients. Rationale and design of a pilot study. Russian Journal of Cardiology. 2021;26(7):4608. (In Russ.) doi:10.15829/1560-4071-2021-4608.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Usova EI, Ionov MV, Alieva AS, et al. An integrated approach for very high cardiovascular risk patients. Intermediate results. Russian Journal of Cardiology. 2022;27(1):4839. (In Russ.) Усова Е. И., Ионов М. В., Алиева А. С. и др. Интегрированное решение для пациентов очень высокого сердечно-сосудистого риска. Промежуточные результаты. Российский кардиологический журнал. 2022;27(1):4839. doi:10.15829/1560-4071-2022-4839.</mixed-citation><mixed-citation xml:lang="en">Usova EI, Ionov MV, Alieva AS, et al. An integrated approach for very high cardiovascular risk patients. Intermediate results. Russian Journal of Cardiology. 2022;27(1):4839. (In Russ.) doi:10.15829/1560-4071-2022-4839.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Pogosova NV, Boycharov IH, Sokolova OYu, Vygodin VA. The New European Question­naire for Assessment of Quality of Life of Patients With Ischemic Heart Disease: HeartQoL. Kardiologiia. 2016;56(8):66-72. (In Russ.) Погосова Н. В., Байчоров И. Х., Соколова О. Ю., Выгодин В. А. Новый европейский опросник HeartQol для оценки качества жизни больных ишемической болезнью сердца. Кардиология. 2016;56(8):66-72.</mixed-citation><mixed-citation xml:lang="en">Pogosova NV, Boycharov IH, Sokolova OYu, Vygodin VA. The New European Question­naire for Assessment of Quality of Life of Patients With Ischemic Heart Disease: HeartQoL. Kardiologiia. 2016;56(8):66-72. (In Russ.) Погосова Н. В., Байчоров И. Х., Соколова О. Ю., Выгодин В. А. Новый европейский опросник HeartQol для оценки качества жизни больных ишемической болезнью сердца. Кардиология. 2016;56(8):66-72.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Messerli FH, Bangalore S, Schmieder RE. Wilder’s principle: pre-treatment value deter­mines post-treatment response. Eur Heart J. 2015;36:576-9. doi:10.1093/eurheartj/ehu467.</mixed-citation><mixed-citation xml:lang="en">Messerli FH, Bangalore S, Schmieder RE. Wilder’s principle: pretreatment value deter­mines post-treatment response. Eur Heart J. 2015;36:576-9. doi:10.1093/eurheartj/ehu467.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet Lond Engl. 2012;380:581-90. doi:10.1016/S0140-6736(12)60367-5.</mixed-citation><mixed-citation xml:lang="en">Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet Lond Engl. 2012;380:581-90. doi:10.1016/S0140-6736(12)60367-5.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sunamura M, ter Hoeve N, van den Berg-Emons HJG, et al. OPTImal CArdiac REhablitation (OPTICARE) following Acute Coronary Syndromes: Rationale and design of a ran­domised, controlled trial to investigate the benefits of expanded educational and beha­vioural intervention programs. Neth Heart J. 2013;21:324-30. doi:10.1007/s12471-013-0422-y.</mixed-citation><mixed-citation xml:lang="en">Sunamura M, ter Hoeve N, van den Berg-Emons HJG, et al. OPTImal CArdiac REhablitation (OPTICARE) following Acute Coronary Syndromes: Rationale and design of a randomised, controlled trial to investigate the benefits of expanded educational and beha­vioural intervention programs. Neth Heart J. 2013;21:324-30. doi:10.1007/s12471-013-0422-y.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2020;41(1):111-88. doi:10.1093/eurheartj/ehz455.</mixed-citation><mixed-citation xml:lang="en">Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal. 2020;41(1):111-88. doi:10.1093/eurheartj/ehz455.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Кухарчук В. В., Ежов М. В.., Сергиенко И. В. и др. Атеросклероз и дислипидемии. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. 2020;1(38):7-42. doi:10.34687/2219-8202.JAD.2020.01.0002.</mixed-citation><mixed-citation xml:lang="en">Kukharchuk VV, Ezhov MV, Sergienko IV, et al. Diagnostics and correction of lipid meta­bolism disorders in order to prevent and treat atherosclerosis. Russian recommendations VII revision. The Journal of Atherosclerosis and Dyslipidemias. 2020;1(38):7-42. (In Russ.) doi:10.34687/2219-8202.JAD.2020.01.0002.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Jia X, Ramsey DJ, Rifai MA, et al. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020;125(6):874-9. doi:10.1016/j.amjcard.2019.12.030.</mixed-citation><mixed-citation xml:lang="en">Jia X, Ramsey DJ, Rifai MA, et al. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020;125(6):874-9. doi:10.1016/j.amjcard.2019.12.030.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Jia X, Al Rifai M, Ramsey DJ, et al. Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System. Am J Med. 2019;132(9):e693-e700. doi:10.1016/j.amjmed.2019.04.002.</mixed-citation><mixed-citation xml:lang="en">Jia X, Al Rifai M, Ramsey DJ, et al. Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System. Am J Med. 2019;132(9):e693-e700. doi:10.1016/j.amjmed.2019.04.002.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Tran C, Vo V, Taylor P, et al. Adherence to lipid monitoring and its impact on treat intensification of LDL-C lowering therapies at an urban academic medical center. J Clin Lipidol. 2022;16(4):491-7. doi:10.1016/j.jacl.2022.05.003.</mixed-citation><mixed-citation xml:lang="en">Tran C, Vo V, Taylor P, et al. Adherence to lipid monitoring and its impact on treat intensification of LDL-C lowering therapies at an urban academic medical center. J Clin Lipidol. 2022;16(4):491-7. doi:10.1016/j.jacl.2022.05.003.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Ammenwerth E, Woess S, Baumgartner C, et al. Evaluation of an Integrated Telemoni­toring Surveillance System in Patients with Coronary Heart Disease. Methods Inf Med. 2015;54(5):388-97. doi:10.3414/ME15-02-0002.</mixed-citation><mixed-citation xml:lang="en">Ammenwerth E, Woess S, Baumgartner C, et al. Evaluation of an Integrated Telemoni­toring Surveillance System in Patients with Coronary Heart Disease. Methods Inf Med. 2015;54(5):388-97. doi:10.3414/ME15-02-0002.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-337. doi:10.1093/eurheartj/ehab484.</mixed-citation><mixed-citation xml:lang="en">Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-337. doi:10.1093/eurheartj/ehab484.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Xu Y, Ye H, Zhu Y, et al. The efficacy of mobile health in alleviating risk factors related to the occurrence and development of coronary heart disease: A systematic review and meta-analysis. Clin Cardiol. 2021;44:609-19. doi:10.1002/clc.23596.</mixed-citation><mixed-citation xml:lang="en">Xu Y, Ye H, Zhu Y, et al. The efficacy of mobile health in alleviating risk factors related to the occurrence and development of coronary heart disease: A systematic review and meta-analysis. Clin Cardiol. 2021;44:609-19. doi:10.1002/clc.23596.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Dorje T, Zhao G, Tso K, et al. Smartphone and social media-based cardiac rehabilitation and secondary prevention in China (SMART-CR/SP): a parallel-group, single-blind, randomised controlled trial. Lancet Digit Health. 2019;1:e363-74. doi:10.1016/S2589-7500(19)30151-7.</mixed-citation><mixed-citation xml:lang="en">Dorje T, Zhao G, Tso K, et al. Smartphone and social media-based cardiac rehabilitation and secondary prevention in China (SMART-CR/SP): a parallel-group, single-blind, randomised controlled trial. Lancet Digit Health. 2019;1:e363-74. doi:10.1016/S2589-7500(19)30151-7.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Барбараш О. Л., Дупляков Д. В., Затейщиков Д. А. и др. Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(4):4449. doi:10.15829/1560-4071-2021-4449.</mixed-citation><mixed-citation xml:lang="en">Barbarash OL, Duplyakov DV, Zateischikov DA, et al. 2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. Russian Journal of Cardio­logy. 2021;26(4):4449. (In Russ.) doi:10.15829/1560-4071-2021-4449.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Jin K, Khonsari S, Gallagher R, et al. Telehealth interventions for the secondary prevention of coronary heart disease: A systematic review and meta-analysis. Eur J Cardiovasc Nurs. 2019;18(4):260-71. doi:10.1177/1474515119826510.</mixed-citation><mixed-citation xml:lang="en">Jin K, Khonsari S, Gallagher R, et al. Telehealth interventions for the secondary prevention of coronary heart disease: A systematic review and meta-analysis. Eur J Cardiovasc Nurs. 2019;18(4):260-71. doi:10.1177/1474515119826510.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ionov MV, Zhukova OV, Yudina YS, et al. Value-based approach to blood pressure telemonitoring and remote counseling in hypertensive patients. Blood Press. 30(1):20-30. doi:10.1080/08037051.2020.1813015.</mixed-citation><mixed-citation xml:lang="en">Ionov MV, Zhukova OV, Yudina YS, et al. Value-based approach to blood pressure telemonitoring and remote counseling in hypertensive patients. Blood Press. 30(1):20-30. doi:10.1080/08037051.2020.1813015.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Blasco A, Carmona M, Fernández-Lozano I, et al. Evaluation of a telemedicine service for the secondary prevention of coronary artery disease. J Cardiopulm Rehabil Prev. 2012;32:25-31. doi:10.1097/HCR.0b013e3182343aa7.</mixed-citation><mixed-citation xml:lang="en">Blasco A, Carmona M, Fernández-Lozano I, et al. Evaluation of a telemedicine service for the secondary prevention of coronary artery disease. J Cardiopulm Rehabil Prev. 2012;32:25-31. doi:10.1097/HCR.0b013e3182343aa7.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Zheng X, Spatz ES, Bai X, et al. Effect of Text Messaging on Risk Factor Management in Patients With Coronary Heart Disease: The CHAT Randomized Clinical Trial. Circ Cardio­vasc Qual Outcomes. 2019;12(4):e005616. doi:10.1161/CIRCOUTCOMES.119.005616.</mixed-citation><mixed-citation xml:lang="en">Zheng X, Spatz ES, Bai X, et al. Effect of Text Messaging on Risk Factor Management in Patients With Coronary Heart Disease: The CHAT Randomized Clinical Trial. Circ Cardio­vasc Qual Outcomes. 2019;12(4):e005616. doi:10.1161/CIRCOUTCOMES.119.005616.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Lear SA, Singer J, Banner-Lukaris D, et al. Improving access to cardiac rehabilitation using the internet: a randomized trial. Stud Health Technol Inform. 2015;209:58-66.</mixed-citation><mixed-citation xml:lang="en">Lear SA, Singer J, Banner-Lukaris D, et al. Improving access to cardiac rehabilitation using the internet: a randomized trial. Stud Health Technol Inform. 2015;209:58-66.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Lee EKP, Poon P, Yip BHK, et al. Global Burden, Regional Differences, Trends, and Health Consequences of Medication Nonadherence for Hypertension During 2010 to 2020: A Meta‐Analysis Involving 27 Million Patients. J Am Heart Assoc. 2022;11:e026582. doi:10.1161/JAHA.122.026582.</mixed-citation><mixed-citation xml:lang="en">Lee EKP, Poon P, Yip BHK, et al. Global Burden, Regional Differences, Trends, and Health Consequences of Medication Nonadherence for Hypertension During 2010 to 2020: A Meta‐Analysis Involving 27 Million Patients. J Am Heart Assoc. 2022;11:e026582. doi:10.1161/JAHA.122.026582.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166:1842-7. doi:10.1001/archinte.166.17.1842.</mixed-citation><mixed-citation xml:lang="en">Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166:1842-7. doi:10.1001/archinte.166.17.1842.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Chow CK, Klimis H, Thiagalingam A, et al. Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome: The TEXTMEDS Randomized Clinical Trial. Circulation. 2022;145:1443-55. doi:10.1161/CIRCULATIONAHA.121.056161.</mixed-citation><mixed-citation xml:lang="en">Chow CK, Klimis H, Thiagalingam A, et al. Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome: The TEXTMEDS Randomized Clinical Trial. Circulation. 2022;145:1443-55. doi:10.1161/CIRCULATIONAHA.121.056161.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Pfaeffli Dale L, Whittaker R, Jiang Y, et al. Text Message and Internet Support for Coronary Heart Disease Self-Management: Results From the Text4Heart Randomized Controlled Trial. J Med Internet Res. 2015;17:e237. doi:10.2196/jmir.4944.</mixed-citation><mixed-citation xml:lang="en">Pfaeffli Dale L, Whittaker R, Jiang Y, et al. Text Message and Internet Support for Coronary Heart Disease Self-Management: Results From the Text4Heart Randomized Controlled Trial. J Med Internet Res. 2015;17:e237. doi:10.2196/jmir.4944.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the manage­ment of arterial hypertension. Eur Heart J. 2018;39:3021-104. doi:10.1093/eurheartj/ehy339.</mixed-citation><mixed-citation xml:lang="en">Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the manage­ment of arterial hypertension. Eur Heart J. 2018;39:3021-104. doi:10.1093/eurheartj/ehy339.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Schutte AE, Gnanenthiran SR. Toward a Better Understanding of Why Cumulative Blood Pressure Is Such a Strong Predictor of Cardiovascular Outcomes. Hypertens Dallas Tex 1979. 2021;78:1267-9. doi:10.1161/HYPERTENSIONAHA.121.18156.</mixed-citation><mixed-citation xml:lang="en">Schutte AE, Gnanenthiran SR. Toward a Better Understanding of Why Cumulative Blood Pressure Is Such a Strong Predictor of Cardiovascular Outcomes. Hypertens Dallas Tex 1979. 2021;78:1267-9. doi:10.1161/HYPERTENSIONAHA.121.18156.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Ionov M, Usova E, Egorov M, et al. Home blood pressure in target range as an additional therapeutic goal in hypertensive patients: a telemonitoring-based analysis. Connect Health. 2022;1:101-11. doi:10.20517/ch.2022.12.</mixed-citation><mixed-citation xml:lang="en">Ionov M, Usova E, Egorov M, et al. Home blood pressure in target range as an additional therapeutic goal in hypertensive patients: a telemonitoring-based analysis. Connect Health. 2022;1:101-11. doi:10.20517/ch.2022.12.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">O’Neil A, Taylor B, Sanderson K, et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the "MoodCare" randomized controlled trial. Ann Behav Med Publ Soc Behav Med. 2014;48:163-74. doi:10.1007/s12160-014-9592-0.</mixed-citation><mixed-citation xml:lang="en">O’Neil A, Taylor B, Sanderson K, et al. Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the "MoodCare" randomized controlled trial. Ann Behav Med Publ Soc Behav Med. 2014;48:163-74. doi:10.1007/s12160-014-9592-0.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">O’Neil A, Hawkes AL, Atherton JJ, et al. Telephone-delivered health coaching improves anxiety outcomes after myocardial infarction: the "ProActive Heart" trial. Eur J Prev Cardiol. 2014;21:30-8. doi:10.1177/2047487312460515.</mixed-citation><mixed-citation xml:lang="en">O’Neil A, Hawkes AL, Atherton JJ, et al. Telephone-delivered health coaching improves anxiety outcomes after myocardial infarction: the "ProActive Heart" trial. Eur J Prev Cardiol. 2014;21:30-8. doi:10.1177/2047487312460515.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Brouwers RWM, van der Poort EKJ, Kemps HMC, et al. Cost-effectiveness of Cardiac Telerehabilitation With Relapse Prevention for the Treatment of Patients With Coronary Artery Disease in the Netherlands. JAMA Netw Open. 2021;4:e2136652. doi:10.1001/jamanetworkopen.2021.36652.</mixed-citation><mixed-citation xml:lang="en">Brouwers RWM, van der Poort EKJ, Kemps HMC, et al. Cost-effectiveness of Cardiac Telerehabilitation With Relapse Prevention for the Treatment of Patients With Coronary Artery Disease in the Netherlands. JAMA Netw Open. 2021;4:e2136652. doi:10.1001/jamanetworkopen.2021.36652.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Bhardwaj V, Spaulding EM, Marvel FA, et al. Cost-effectiveness of a Digital Health Intervention for Acute Myocardial Infarction Recovery. Med Care. 2021;59:1023-30. doi:10.1097/MLR.0000000000001636.</mixed-citation><mixed-citation xml:lang="en">Bhardwaj V, Spaulding EM, Marvel FA, et al. Cost-effectiveness of a Digital Health Intervention for Acute Myocardial Infarction Recovery. Med Care. 2021;59:1023-30. doi:10.1097/MLR.0000000000001636.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
